General Hospital "Dr. Anđelko Višić" Bjelovar
- Address
- Ul. Antuna Mihanovića 8, 43000 Bjelovar, Croatia
Cardiovascular Diseases
The Department of Neurology at General Hospital "Dr. Anđelko Višić" Bjelovar is involved in research focused on cardiovascular diseases, with attention to acute ischemic stroke and high-risk transient ischemic attack. These trials are designed to assess whether new treatment options can better reduce the chance of another stroke and improve outcomes after a cerebrovascular event.
- Studying acute ischemic stroke and high-risk transient ischemic attack
- Evaluating a potential therapy aimed at lowering the risk of recurrent stroke
- Supporting better prevention and treatment strategies in neurology and cardiovascular care
This research reflects a strong interest in improving recovery and long-term protection for patients affected by serious cerebrovascular conditions.
Digestive System Diseases
Clinical trials at this site also address digestive system diseases, especially ulcerative colitis and moderate to severe active ulcerative colitis. The studies are aimed at comparing treatment options and finding therapies that may help control inflammation, relieve symptoms, and support remission in people living with this chronic gastrointestinal condition.
- Focusing on ulcerative colitis and moderately to severely active UC
- Comparing a proposed biosimilar with an established treatment
- Testing whether new approaches can improve clinical remission and disease control
This area of research is centered on better treatment effectiveness and access to options for patients with ongoing inflammatory bowel disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Eli Lilly & Co.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital "Dr. Anđelko Višić" Bjelovar
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-08-04 | 2023-08-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.